

## SUANFARMA announces a collaboration with Reyoung Pharmaceutical to expand the existing portfolio of anti-infective and antibacterial products.

- The main objective of the collaboration is to introduce **generic pharmaceutical ingredients** to the market for the **treatment of infectious diseases**.
- The development of new manufacturing processes with **cutting-edge technologies**, based on **green chemistry** and with the **optimisation of resources** as the central focus, will lead to the highest quality products at more affordable prices.
- The technology developed by SUANFARMA is expected to fill **global supply shortages** of these antibacterial products.

**Madrid, October 18th, 2023** – SUANFARMA, through its **R&D division**, celebrates the historic agreement reached with Reyoung Pharmaceutical, a leader in the manufacture of active ingredients since 1966. Reyoung's decades of experience as an exporter of products worldwide are perfectly aligned with SUANFARMA, which has been present in the pharmaceutical and nutritional ingredients market for 30 years.

This **bilateral agreement** between the Spanish multinational, providing the technology internally developed and its partner Reyoung with a well-known trustability in manufacturing capabilities, will constitute a strategic cooperation for **anti-infective and antibacterial** API production. These drugs are crucial to guaranteeing the health of the population. Both companies consider it essential to ensure the supply of this therapeutic line, especially in these times of shortages and increased supply chain uncertainty for the global pharma industry.

SUANFARMA is committed to health and innovation, which is why it develops and produces accessible raw materials in accordance with the highest regulatory requirements of the EMA or the FDA. Moreover, the company is also devoted to environmentally responsible practices, embracing **green chemistry** and prioritizing environmental protection. To this end, their robust R&D team works on the **development of technologies** to achieve maximum efficiency in its processes, to incorporate **cutting-edge active ingredients** into its portfolio.

The innovative technology developed by SUANFARMA involves Flow Chemistry, improving yields, selectivity and reproducibility of the processes. It minimizes reaction times and requires smaller quantities of reagents and solvents, reducing raw material use and environmental impact. In addition, this technique is generally safer than traditional synthesis, reducing the risk of explosions and leaks of hazardous reagents.

*"We are thrilled to join forces with SUANFARMA as we embark on this transformative collaboration, which marries innovation with exceptional product delivery. This alliance marks the beginning of an exciting journey, and we are confident that our collaboration will deliver immense value to our customers and partners by harnessing the unique strengths and capabilities of each organization."* Declares Mr Xie- Reyoung Pharmaceutical Vice-President

*"This important strategic agreement between Reyoung and SUANFARMA highlights our shared commitment to technology-driven innovation and maximizing efficiency in order to provide superior products to the patients."*

*Reyoung's exceptional partnership as our ally strengthens our global position, marking the first milestone in what we anticipate will be an immensely promising collaboration between our organizations." Says Javier Calvo, R&D Director.*

This significant agreement is expected to be the beginning of a strong collaboration between the two partners, with very promising results for the benefit of the patients.

We are fully committed to enhancing the health of both humans and animals, striving to prevent diseases in a sustainable manner.

### **About SUANFARMA**

SUANFARMA founded in 1993, is a B2B life science partner specialized in the development, production, and commercialization of ingredients for the pharmaceutical, veterinary and nutraceutical industries.

In SUANFARMA we offer our **CDMO capacity** for fermentation and chemical synthesis projects, offering a **"One Stop Shop" service** with a solid track record, and which allows to achieve success in the development, scaling, manufacturing, and commercialization of an API, either innovative or generic.

All facilities comply with the highest existing regulations in the pharmaceutical industry. With the support of a consolidated and strong commercial network with 12 local offices placed strategically around the world, SUANFARMA provides its services to more than 3.000 active customers in over 70 countries. More information: [www.suanfarma.com](http://www.suanfarma.com)

### **About Reyoung**

Reyoung is a modern, vertically integrated pharmaceutical company, focused on **enhancing the quality of its products** by using innovation as the basis of the process.

Its main strength is its large production capacity, with 3 different plants and 30 workshops for the manufacturing of both active pharmaceutical ingredients and finished products. Annually, Reyoung is able to provide therapeutic solutions for more than 500 million patients worldwide with up to 650 million FDF dosage per year.

It is a company that is committed to quality and operates under GMP (Good Manufacturing Practices) certification, implementing the highest quality standards required by international health authorities and is also a strong financial partner, with annual sales up to 540 million USD from FDF market. More information: <http://reyoung.com/s.php/en/>

### **Contact**

Silvia Martín de Cáceres

**Head of Marketing & Communications**

[silviamartin@suanfarma.com](mailto:silviamartin@suanfarma.com)

T + 34 91 344 68 90

C / Einstein, 8

28108, Alcobendas - Madrid - Spain